Aurora Cannabis Inc.
NASDAQ:ACBDrug Manufacturers - Specialty & Generic
+$0.02 today
- Market cap
- $289.28M
- Beta
- 1.34
- P/E (TTM)
- -3.2
- EPS (TTM)
- -$1.31
Volume 0.92M
Average 1.00M
ACB Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Aurora Cannabis Inc.NASDAQ: ACB
Depreciation & Amortization · Q4 FY2026 · quarter ended Mar 2026
Depreciation & amortization turns negative
Q4 FY2026 depreciation & amortization was -CA$4.62M, compared with CA$5.95M a year earlier. Trailing-twelve-month depreciation & amortization was CA$14.19M. Over 3 fiscal years it compounded at -31.1% a year.
Context
- Depreciation & amortization amounted to 4.4% of revenue in FY2026, down 2.1 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2026 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near -CA$4.62M or moves back toward the trailing-twelve-month quarterly average of CA$3.55M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
CAD · from the cash flow
- Latest · FY2026
- 14.23M CAD
- Year-over-year change
- -36.9%
- 4-year CAGR
- -37.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 14.23M | -36.9% |
| FY2025 | 2025-03-31 | 22.55M | -31.2% |
| FY2024 | 2024-03-31 | 32.78M | -24.8% |
| FY2023 | 2023-03-31 | 43.57M | -53.5% |
| FY2022 | 2022-06-30 | 93.66M | — |
Depreciation & Amortization vs competitors
How ACB compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -37.1% is the 9th highest of 10, against a peer median of -7.7%.
- Depreciation & amortization amounts to 4.6% of revenue for ACB, versus a peer median of 6.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$39.79M CAD | -7.7% | -14.0% | 12.7% | |
| LTM Apr 2026 | CA$20.61M CAD | -9.5% | -6.9% | 3.1% | |
| LTM Mar 2026 | CA$19.77M CAD | +37.9% | — | 7.2% | |
| LTM Mar 2026 | CA$14.19M CAD | -37.1% | -31.1% | 4.6% | |
| LTM Mar 2026 | $9.76M USD | — | -23.7% | 7.2% | |
| LTM Mar 2026 | $6.34M USD | -2.8% | +26.1% | 15.2% | |
| LTM Mar 2026 | $4.17M USD | -34.0% | -5.9% | 10.8% | |
| LTM Mar 2026 | $2.79M USD | +41.0% | +9.9% | 0.8% | |
| LTM Mar 2026 | $2.76M USD | -127.4% | -55.7% | 1.3% | |
| LTM Mar 2026 | $528K USD | -25.9% | -17.1% | 6.3% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $239K USD | +39.8% | +18.2% | 2.3% |
| Peer median (excluding ACB) | — | -7.7% | -6.9% | 6.8% | |
Competitors are the stored peer set for ACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Jun 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Net Income | (1.72B) | (265.33M) | (57.08M) | 15.76M | (58.77M) |
| Depreciation & Amortization | 93.66M | 43.57M | 32.78M | 22.55M | 14.23M |
| Deferred Income Tax | (2.19M) | (18.4M) | (1.67M) | (3.19M) | 55.14K |
| Stock-Based Compensation | 13.76M | 16.89M | 12.72M | 11.52M | 7.29M |
| Change in Working Capital | 52.65M | (25.12M) | (15.54M) | 10.21M | (9.24M) |
| Accounts Receivables | 18.34M | 5.53M | (4.5M) | 5.24M | (8.17M) |
| Inventory | 21.07M | 49.03M | 3.87M | (15.05M) | 65.93M |
| Accounts Payables | 6.77M | (8.06M) | (15.7M) | 14.91M | (8.06M) |
| Other Working Capital | 6.48M | (71.61M) | 790K | 5.11M | (58.93M) |
| Other Non-Cash Items | 1.45B | 190.11M | (39.71M) | (40.85M) | 40.18M |
| Operating Cash Flow | (110.27M) | (115.82M) | (68.51M) | 16.01M | (13.55M) |
| Capital Expenditures | (32.21M) | (12.13M) | (16.83M) | (18.86M) | (22.6M) |
| Acquisitions (Net) | (23.42M) | (18.54M) | (5.55M) | 0 | 1.1M |
| Purchases of Investments | 0 | 0 | 0 | 0 | (52.35M) |
| Sales of Investments | 0 | 3.36M | 4.99M | 5.49M | 0 |
| Other Investing Activities | 19.46M | 16K | 14.02M | (956K) | 235.61K |
| Investing Cash Flow | (36.17M) | (27.29M) | (3.36M) | (14.33M) | (73.62M) |
| Debt Repayment | (170.83M) | — | (85.37M) | (805K) | (5.02M) |
| Common Stock Issued | 350.19M | 73.19M | 37.92M | 820K | 9.94M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (31.58M) | (95.21M) | (475K) | (131K) | (154.4K) |
| Financing Cash Flow | 147.78M | (56.48M) | (47.92M) | (116K) | 9.79M |
| Effect of Forex Changes | 15.01M | 15.54M | 297K | 264K | 10.56M |
| Net Change in Cash | 16.35M | (140.01M) | (119.5M) | 1.83M | (66.81M) |
| Free Cash Flow | (142.48M) | (127.95M) | (85.34M) | (2.85M) | (36.15M) |
Aurora Cannabis Inc.
NASDAQ:ACB
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.